Evaluation of hyperthermic intrathoracic chemotherapy (HITHOC)

Evaluation of hyperthermic intrathoracic chemotherapy (HITHOC) - HITHOC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00015012

Enrollment

250

Registered

2018-08-03

Start date

2020-01-10

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C45.0 C38.4

Interventions

Group 1: Retrospective analysis of surgical cytoreduction in combination with intraoperative HITHOC (hyperthermic intrathoracic chemotherapy)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - HITHOC after surgical cytoreduction - malignant pleural tumor

Exclusion criteria

Exclusion criteria: - therapy without HITHOC - HITHOC without surgical cytoreduction

Design outcomes

Primary

Measure	Time frame
Quality assurance and implementation of intraoperative HITOC after surgical cytoreduction	—

Secondary

Measure	Time frame
- Dosing of intrathoracic chemotherapy (cisplatin) during HITOC - Postoperative renal insufficiency including conservative therapy and dialysis after HITOC, also depending to the dosage of cisplatin - In-hospital mortality after HITOC and surgical cytoreduction - Postoperative complications and morbidity (e.g. surgical revision) - Technical development of HITOC, changes in perioperative management and extend of complications within the last years	—

Measure

Time frame

- Dosing of intrathoracic chemotherapy (cisplatin) during HITOC - Postoperative renal insufficiency including conservative therapy and dialysis after HITOC, also depending to the dosage of cisplatin - In-hospital mortality after HITOC and surgical cytoreduction - Postoperative complications and morbidity (e.g. surgical revision) - Technical development of HITOC, changes in perioperative management and extend of complications within the last years

—

Countries

Germany

Contacts

Public ContactMichael Ried

Abteilung für Thoraxchirurgie, Universitätsklinikum Regensburg

michael.ried@ukr.de0941/944-9801

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 18, 2026